Email

The FDA’s Green Light Means Marijuana’s “Second Wave” Is Coming

1 | By Wall Street Insights and Indictments Staff

Two weeks ago, we told you about “Legal Marijuana’s Biggest Day Yet,” when the Canadian Senate passed a bill earlier this month legalizing the use of recreational marijuana, becoming the second nation aside from Uruguay to do so.

This news was huge. Not only did legalization open the doors for Canadians to spend up to $4.34 billion on legal cannabis products in 2019, which could propel cannabis companies’ stock prices to extraordinary highs, it also preceded a huge event that occurred just this past Monday:

The FDA approved the first cannabis-based drug on June 25, 2018.

This drug, commissioned by GW Pharmaceuticals plc (NasdaqGM:GWPH), called Epidiolex, is a twice-daily oral treatment used for patients with severe epilepsy.

Now, keep in mind, these cannabis-based drugs have nothing to do with the stuff people smoke or vape to get high. They have nothing to do with the recreational legalization in Canada, California, or any other state or country that will legalize recreational marijuana in the future. These drugs are non-“high” methods of treatment. In other words, patients do not experience any of the psychedelic properties that come with recreational marijuana. These drugs utilize the numerous medical benefits that come from the plant.

This industry for the clean, medical use of marijuana properties will shake up a $1.112 trillion market, and Epidiolex’s approval is what will set the tone for the industry’s next steps.

Here’s how this industry could take you from “zero to fortune” within the next 18 months alone…

The Single Biggest Moneymaking Opportunity This Year

When you think of unbelievable gains, you think of companies like Apple Inc. (NasdaqGS:AAPL), Netflix Inc. (NasdaqGS:NFLX), and Amazon.com Inc. (NasdaqGS:AMZN) – all of which have grown by tens of thousands of percentage points in the past two decades.

But instead of taking nearly twenty years to make it big, what we’re looking at now could skyrocket in a matter of months.

For example, Canopy Growth Corp. (NYSE:CGC) was just $0.05 a share at the beginning of March 2014. But as legal marijuana in Colorado became a reality and U.S. state support for medical marijuana started gaining steam, the stock leaped to $3.37 a share. That’s a quick, but rare, 6,600% gain.

[URGENT] It’s taken eight LONG years to develop this algorithm

Then, following Justin Trudeau’s announcement of his support for legalizing marijuana across Canada, Canopy went from under $4 a share to $12.60.

After that, when California’s announced legalization on January 1, Canopy’s stock shot from $7.83 a share to a high of $37.48 in January.

Altogether, rocketing from $0.05 a share to a little over $37.00 equals a massive, exceptional 74,860% gain over the long term – all driven by four crucial events.

These events were part of the single biggest moneymaking opportunity you’re likely to see in your lifetime.

And it’s not over yet.

The Man Behind the Curtain

Here at Money Map Press, we have one man who we knew could take on the challenge of effectively explaining the benefits of medical marijuana, as well as pick the best of the best companies that could see record-breaking gains in the near future.

His name is Ernie Tremblay, and he’s our Chief Scientific Officer and editor of our Biotech Insider Alert research service.

[CRUCIAL] If you’re not getting rich right now, listen to this

Before even considering a company to recommend to his readers, the company must meet three of Ernie’s crucial criteria:

  1. Does the science work?
  2. Is there a need? 
  3. Will doctors prescribe it?

And, in the next few days, Ernie is going to preview to a select few people a handful of medical marijuana companies that he sees as having huge profit potential.

But before we get to those, here’s how we know to expect the best from Ernie…

In 2017, Ernie recommended Zogenix Inc. (NasdaqGM:ZGNX) to his readers a few weeks before a critical data release. At the time, the stock was trading at only $14.25.

Within a month, ZGNX’s stock had doubled to $38.90, and rose to an eventual high of $45.25 shortly after…

In 2014, while working on cardiovascular research, Ernie came across a small company doing amazing work in the area of arterial disease. He recommended it to members of Biotech Insider Alert, and within three months, it soared from about $35.00 to $114.84…

A little earlier, in 2013, a company called Sangamo Therapeutics Inc. (NasdaqGS:SGMO) developed a breakthrough treatment for HIV. He recommended it while it was climbing from $10.30 to as high as $23.04 in less than four months…

And that’s just the tip of the iceberg.

For some time now, Ernie has been meticulously studying curative properties of cannabis, painstakingly ensuring that these companies he’s picked have the potential to return the same kinds of incredible gains.

And everything he’s seen has told him that cannabis is the single most important medical treatment of our lifetimes – on the scale of penicillin regarding the number of people it could help, or insulin in terms of the quality of life it can offer folks who have been suffering terribly.

These companies are the key to alleviating symptoms in conditions like chronic pain, Parkinson’s, epileptic seizures, Alzheimer’s, glaucoma, cancer, and beyond…

The pharmaceutical industry has been handcuffed when it comes to creating pharmaceutical grade medication using pure cannabis – given the drug’s legal status.

But all that changed the afternoon of June 25, 2018 when the FDA announced its first-ever approval of an all-natural cannabis prescription drug in U.S. history, Epidiolex.

Everything’s about to change. Don’t be the one who missed out on the biggest medical breakthrough of the twenty-first century.

Sincerely,

The Wall Street Insights & Indictments Research Team

One Response to The FDA’s Green Light Means Marijuana’s “Second Wave” Is Coming

Leave a Reply

Your email address will not be published. Required fields are marked *